S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Phio Pharmaceuticals Stock Forecast, Price & News

-0.06 (-4.84%)
(As of 12/3/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
173,211 shs
Average Volume
744,191 shs
Market Capitalization
$15.97 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive PHIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Phio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Phio Pharmaceuticals logo

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.


Phio Pharmaceuticals' (PHIO) "Buy" Rating Reaffirmed at HC Wainwright
November 15, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$20 thousand
Book Value
$1.87 per share


Net Income
$-8.79 million
Pretax Margin




Free Float
Market Cap
$15.97 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.80 out of 5 stars

Medical Sector

844th out of 1,388 stocks

Pharmaceutical Preparations Industry

405th out of 668 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Phio Pharmaceuticals (NASDAQ:PHIO) Frequently Asked Questions

Is Phio Pharmaceuticals a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phio Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Phio Pharmaceuticals stock.
View analyst ratings for Phio Pharmaceuticals
or view top-rated stocks.

How has Phio Pharmaceuticals' stock price been impacted by COVID-19?

Phio Pharmaceuticals' stock was trading at $2.77 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PHIO stock has decreased by 57.4% and is now trading at $1.18.
View which stocks have been most impacted by COVID-19

When is Phio Pharmaceuticals' next earnings date?

Phio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Phio Pharmaceuticals

How were Phio Pharmaceuticals' earnings last quarter?

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.03.
View Phio Pharmaceuticals' earnings history

What price target have analysts set for PHIO?

1 analysts have issued 12 month price objectives for Phio Pharmaceuticals' stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate Phio Pharmaceuticals' stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 408.5% from the stock's current price.
View analysts' price targets for Phio Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Phio Pharmaceuticals' key executives?

Phio Pharmaceuticals' management team includes the following people:
  • Gerrit Dispersyn, President, Chief Executive Officer & Director (LinkedIn Profile)
  • James Cardia, Vice President-Business Operations
  • Caitlin Kontulis, Secretary, VP-Finance & Administration
  • Simon Fricker, Vice President-Research

What other stocks do shareholders of Phio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phio Pharmaceuticals investors own include DURECT (DRRX), CymaBay Therapeutics (CBAY), Ocugen (OCGN), Akero Therapeutics (AKRO), Ampio Pharmaceuticals (AMPE), Boxlight (BOXL), Evofem Biosciences (EVFM), Fulcrum Therapeutics (FULC), Jaguar Health (JAGX) and Milestone Pharmaceuticals (MIST).

What is Phio Pharmaceuticals' stock symbol?

Phio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHIO."

Who are Phio Pharmaceuticals' major shareholders?

Phio Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Two Sigma Advisers LP (1.13%), Millennium Management LLC (0.91%), Geode Capital Management LLC (0.79%), BlackRock Inc. (0.26%), Cetera Investment Advisers (0.22%) and Citadel Advisors LLC (0.00%). Company insiders that own Phio Pharmaceuticals stock include Gerrit Dispersyn and Robert L Ferrara.
View institutional ownership trends for Phio Pharmaceuticals

Which major investors are selling Phio Pharmaceuticals stock?

PHIO stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc..
View insider buying and selling activity for Phio Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Phio Pharmaceuticals stock?

PHIO stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Two Sigma Advisers LP, Cetera Investment Advisers, Geode Capital Management LLC, and Citadel Advisors LLC. Company insiders that have bought Phio Pharmaceuticals stock in the last two years include Gerrit Dispersyn, and Robert L Ferrara.
View insider buying and selling activity for Phio Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Phio Pharmaceuticals?

Shares of PHIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Phio Pharmaceuticals' stock price today?

One share of PHIO stock can currently be purchased for approximately $1.18.

How much money does Phio Pharmaceuticals make?

Phio Pharmaceuticals has a market capitalization of $15.97 million and generates $20 thousand in revenue each year. The company earns $-8.79 million in net income (profit) each year or ($1.21) on an earnings per share basis.

How many employees does Phio Pharmaceuticals have?

Phio Pharmaceuticals employs 10 workers across the globe.

What is Phio Pharmaceuticals' official website?

The official website for Phio Pharmaceuticals is phiopharma.com.

Where are Phio Pharmaceuticals' headquarters?

Phio Pharmaceuticals is headquartered at 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752.

How can I contact Phio Pharmaceuticals?

Phio Pharmaceuticals' mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The company can be reached via phone at (508) 767-3861, via email at [email protected], or via fax at 508-767-3862.

This page was last updated on 12/5/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.